Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY374571 is an experimental small molecule inhibitor that targets enzymes involved in folate metabolism. It is a glutamic acid derivative designed to inhibit human methylenetetrahydrofolate dehydrogenase/cyclohydrolase (MTHFD1), a key enzyme in one-carbon metabolism and nucleotide biosynthesis[1][8][9]. The compound has been used as a tool molecule for biochemical studies and structure-based drug design targeting folate-dependent enzymes. While it demonstrates inhibitory activity against MTHFD1 and related enzymes such as FolD (bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase), it has not advanced beyond preclinical or early pharmacokinetic evaluation[8][9]. Its mechanism of action involves competitive inhibition at the active site of these oxidoreductases/hydrolases critical for purine and amino acid biosynthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LY374571.